Bereich
Dermatologie | Venerologie | Allergologie
DERMA · Dept. Interdisziplinäre Medizinische Dienste
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
11.07.2022
Klinische Forschung - 11.07.2022 - 31.12.2026
Laufend
Projektleitung: Wagner Nikolaus
Two cohort registry study for patients with advanced CSCC treated with Cemiplimab or other approaches
01.07.2022
Klinische Forschung - 01.07.2022 - 31.12.2025
Laufend
Projektleitung: Wagner Nikolaus
Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)
14.02.2022
Klinische Forschung - 14.02.2022 - 31.12.2025
Laufend
Projektleitung: Cozzio Antonio
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study
25.01.2022
Klinische Forschung - 25.01.2022 - 25.01.2022
Automatisch geschlossen
Projektleitung: Cozzio Antonio
A multicenter, prospective observational RWE study to assess Patient-reported wellbeing using tildrakizumab in a live setting – POSITIVE Study
18.01.2022
Klinische Forschung - 18.01.2022 - 31.12.2024
Laufend
Projektleitung: Saulite Ieva
Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate -to -severe plaque psoriasis and inadequate response to ustekinumab; COBRA / Phase 4 – efficacy trial A randomised, blinded, parallel-group, multi-site, clinical trial
13.09.2021
Klinische Forschung - 13.09.2021 - 16.11.2022
Abgeschlossen
Projektleitung: Cozzio Antonio
Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, national, prospective, longitudinal, non-interventional study in Switzerland – BERINGMELANOMA
07.09.2021
Klinische Forschung - 07.09.2021 - 01.10.2027
Laufend
Projektleitung: Wagner Nikolaus
Development of the European Organisation for Research and Treatment of Cancer (EORTC)/ Cutaneous Lymphoma Task Force (CLTF) questionnaire to assess HRQoL in cutaneous lymphoma
01.02.2021
Klinische Forschung - 01.02.2021 - 25.08.2023
Laufend
Projektleitung: Cozzio Antonio
Translation of pre-treatment tumor kinetics and clinical and serological markers of the immune system in the treatment of advanced melanoma
01.01.2021Bei diesem Projekt geht es um die Charakterisierung des Therapieansprechens von Melanommetastasen unter Systemtherapie mit anti-PD-1 Antikörpern, kombinierter Immuntherapie mit dem anti-PD-1 Antikörper Nivolumab und dem anti-CTLA-4 Antikörper Ipilimu...
Klinische Forschung - 01.01.2021 - 31.12.2021
Abgeschlossen
Projektleitung: Wagner Nikolaus
PH-L19IL2TNFNMSC-04/19 A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions
02.08.2020
Klinische Forschung - 02.08.2020 - 25.01.2030
Laufend
Projektleitung: Flatz Lukas
Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)
15.07.2016
Klinische Forschung - 15.07.2016 - 15.10.2019
Automatisch geschlossen
Projektleitung: Flatz Lukas
Mitarbeiter/innen: Diem Stefan
A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
25.06.2016
Klinische Forschung - 25.06.2016 - 31.12.2027
Laufend
Projektleitung: Cozzio Antonio
Vaccine and immunotherapy induced CD8+ T cell responses against auto-, neo- and foreign antigens
01.01.2016The growing incidence of melanoma is an increasing threat, and effective treatment options for advanced forms of melanoma are scarce. Although recently approved targeted- and immunotherapies have shown objective beneficial effects in metastatic melan...
Grundlagenforschung - 01.01.2016 - 31.12.2019
Automatisch geschlossen
Projektleitung: Flatz Lukas
Mitarbeiter/innen: Ring Sandra, Królik Michał Wojciech, Berner Fiamma
Long-Term Benefits and Safetyof Systematic Psoriasis Therapy: Swiss Registry on the Treatment of System Psoriasis with Biologics and Systemic Therapeutigs based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
19.07.2012
Klinische Forschung - 19.07.2012 - 19.07.2012
Automatisch geschlossen
Projektleitung: Anliker Mark
Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions
19.05.2012Purpose: A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions
Klinische Forschung - 19.05.2012 - 19.06.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
19.02.2012The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and ad...
Klinische Forschung - 19.02.2012 - 19.06.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
31.01.2012
Klinische Forschung - 31.01.2012 - 31.12.2030
Laufend
Projektleitung: Cozzio Antonio
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
15.11.2011Purpose: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Klinische Forschung - 15.11.2011 - 01.12.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
15.11.2011The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the q...
Klinische Forschung - 15.11.2011 - 19.04.2015
Automatisch geschlossen
Projektleitung: Anliker Mark
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
19.10.2011This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Klinische Forschung - 19.10.2011 - 19.09.2012
Automatisch geschlossen
Projektleitung: Anliker Mark